Yahoo
Shanghai - Delayed Quote CNY

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS)

86.34 +0.47 (+0.55%)
At close: 3:00:00 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
Name Title Pay Exercised Year Born
Mr. Qing Zhu Ph.D.
GM & Director -- -- 1981
Ms. Chun Fang Li
Accounting Supervisor & CFO -- -- 1980
Mr. Zhenyu Yuan
Deputy GM, Core Technical Personnel & Employee Representative Director -- -- 1977
Mr. Lantao Guo
Deputy GM & Core Technical Personnel -- -- 1966
Mr. Ke Chen
Senior Director -- -- 1980
Ms. Dong Mei Yan
Board Secretary -- -- --
Ms. Hongjie Lu
Core Technical Staff -- -- 1983
Ms. Liwen Wang
Core Technical Staff -- -- 1982

Shanghai MicroPort Endovascular MedTech Co., Ltd.

No. 1, Lane 3399
SIMZ Century Medicine Park Kangxin Road Pudong New District
Shanghai, 201318
China
86 21 3813 9300 https://www.endovastec.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
822

Description

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic stent graft system; and Hercules, a thoracic stent graft system with low profile delivery system. It also provides Minos, an abdominal aortic stent graft and delivery System; Aorfix, an endovascular device designed for treating abdominal aortic aneurysms; Altura, a device designed for the endovascular repair of abdominal aortic aneurysms; Aegis, a bifurcated aortic stent graft system; and L-REBOA, an aortic occlusion balloon catheter. In addition, the company offers Reewarm PTX, a drug coated balloon PTA catheter; ReeAmber, a PTA balloon dilatation catheter; Reewarm, a PTA balloon dilatation catheter; Ryflumen, a peripheral high-pressure balloon dilatation catheter; and CROWNUS, a peripheral stent system; HawkMaster, a detachable fibered embolization coils; HawkNest, a fibered embolization coils; Veryan BM3D, which is designed for the treatment of symptomatic de novo lesions in the native superficial femoral artery; Vflower, a venous stent system; SeaDragon, a PTA balloon dilatation catheter; Vewatch, a vena cava filter; Vepack, a snare retrieval kit; VeinPro, an endovenous radiofrequency closure system; Reflow-speX, a support catheter; and DEMANTOID, a peripheral vascular guide wire. Further, it provides Tipspear, a transjugular liver access set. Shanghai MicroPort Endovascular MedTech Co., Ltd. was incorporated in 2012 and is based in Shanghai, the People's Republic of China.

Corporate Governance

Shanghai MicroPort Endovascular MedTech Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

October 20, 2026 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: